文献速递腹部技术与安全PETCT

18F-氟胸苷正电子发射断层显像/计算机断层显像对胃癌腹膜转移的成像:一项概念验证研究

Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study.
PubMed 文献 · Br J Radiol · 2018-06-27

这项概念验证研究纳入19例经CT证实腹膜转移的胃腺癌患者,其中15例(78.9%)为弥漫型组织学,评估18F-氟胸苷PET/CT检测腹膜转移的灵敏度。结果显示腹膜转移、原发灶和淋巴结转移的检测灵敏度分别为73.7%、100%和72.7%,检查期间及之后无患者发生不良事件。作者认为18F-氟胸苷PET/CT是检测胃癌腹膜转移的敏感方法。

要点

  • 18F-氟胸苷PET/CT检测胃癌腹膜转移的灵敏度为73.7%,原发灶为100%,淋巴结转移为72.7%。
  • 腹膜转移灶的SUVmax范围为1.697-13.21,原发灶为2.71-22.01,淋巴结转移为2.079-12.61。
  • 19例患者中15例(78.9%)为弥漫型组织学,检查期间及之后无患者发生不良事件。

核心结论

  • 这项概念验证研究显示18F-氟胸苷PET/CT是检测胃癌腹膜转移的敏感方法,为未来研究该方法检测临床非显性腹膜转移的临床效用铺平了道路。

研究设计与样本

  • 这是一项概念验证研究,纳入19例经组织学证实的胃腺癌患者,均在注册前4周内通过CT检出明确的腹膜转移,且注册前4周内未接受过腹膜转移治疗。
  • 18F-氟胸苷PET/CT在国家癌症中心医院进行,图像由两名放射科医生独立评估,检查前后进行安全性评估。

关键影像表现/征象

  • 腹膜转移、原发灶和淋巴结转移的检测灵敏度分别为73.7%、100%和72.7%。
  • 腹膜转移灶的SUVmax范围为1.697-13.21,原发灶为2.71-22.01,淋巴结转移为2.079-12.61。

诊断标准与关键数值

  • 主要终点为腹膜转移的检测灵敏度,结果为73.7%。
  • 原发灶检测灵敏度为100%,淋巴结转移检测灵敏度为72.7%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Peritoneal metastasis (PM) is the most frequent form of metastasis in gastric cancer (GC). The sensitivity of detecting PM by pre-operative imaging modalities is low. Utility of positron emission tomography (PET) with 18F-fluodeoxyglucose (FDG) for GC is limited, because diffuse-type tumors are not FDG-avid. 18F-fluothymidine ([F-18]FLT) is a radiotracer that reflects cellular proliferation and the utility of [F-18]FLT-PET in GC has been reported. In this proof-of-concept study, we explored the ability of [F-18]FLT-PET/CT to detect PM of GC previously identified by other imaging modalities.

METHODS: The key eligibility criteria were as follows; (i) histologically proven gastric adenocarcinoma; (ii) evident PM detected by CT performed within 4 weeks prior to registration; (iii) no prior treatment of PM within 4 weeks before registration. [F-18]FLT-PET/CT was performed at National Cancer Center Hospital, and [F-18]FLT-PET/CT images were evaluated independently by two radiologists. Safety assessments were carried out before and after [F-18]FLT-PET/CT. The primary end point was the detection sensitivity of PM.

RESULTS: A total of 19 eligible patients were analyzed, of which 15 (78.9%) had diffuse-type histology. Detection sensitivity of PM, primary lesion, and lymph node metastasis were 73.7% [maximum standardized uptake value (SUVmax): 1.697-13.21], 100% (SUVmax: 2.71-22.01), and 72.7% (SUVmax: 2.079-12.61), respectively. No patients experienced adverse events during or after [F-18]FLT-PET/CT.

CONCLUSION: This proof-of-concept study shows that [F-18]FLT-PET/CT is a sensitive method for detecting PM in GC, and paves the way for future studies investigating the clinical utility of this approach for the detection of clinically non-evident PM in GC. Advances in knowledge: This proof-of-concept study found that [F-18]FLT-PET/CT is a sensitive method for detecting peritoneal metastases in GC.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Honma Y, Terauchi T, Tateishi U, et al. Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study. Br J Radiol. 2018. PMID: 29916721. doi:10.1259/bjr.20180259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。